FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381336668> ?p ?o ?g. }

• W4381336668 abstract "Abstract Lebrikizumab (LEB) is a novel, high affinity monoclonal antibody that selectively binds to interleukin (IL)-13. Lebrikizumab has been shown to provide robust improvements in signs and symptoms in adolescent and adult patients with moderate-to-severe AD across three phase 3 clinical trials (ADvocate1, ADvocate2 and ADhere). However, little is known about the efficacy of LEB in difficult to treat regions such as the face and hands. This study aims to report efficacy of LEB in improving facial and hand dermatitis. ADvocate1 and ADvocate2 assessed LEB 250 mg every 2 weeks (LEBQ2W) vs. placebo for 16 weeks in monotherapy. ADhere compared low-to-mid potency topical corticosteroids (TCS) in addition to LEB Q2W vs. TCS and placebo for 16 weeks. In all trials, clinicians assessed for the presence or absence of facial and hand dermatitis. If present at baseline, at Week 16, clinicians assessed the change from baseline on a scale of cleared, improved, no change or worsened. Patients with improved or cleared dermatitis are described. In ADvocate1 at baseline, facial dermatitis was identified in 71.4% (202/283) of LEBQ2W patients and 80.9% (114/141) of placebo. At Week 16, 61.9% (125/202; P &lt; 0.001) of LEBQ2W were improved or cleared vs. 31.6% (36/114) of placebo. At baseline, hand dermatitis was identified in 72.1% (204/283) of LEBQ2W patients vs. 73.0% (103/141) of placebo. At Week 16, 67.2% (137/204; P &lt; 0.001) of LEBQ2W were improved or cleared vs. 29.1% (30/103) of placebo. In ADvocate2 at baseline, facial dermatitis was identified in 73.7% (207/281) of LEBQ2W patients and 78.8% (115/146) of placebo. At Week 16, 57.5% (119/207; P &lt; 0.001) of LEBQ2W were improved or cleared vs. 21.7% (25/115) of placebo. At baseline, hand dermatitis was identified in 73.3% (206/281) of LEBQ2W patients and 72.6% (106/146) of placebo. At Week 16, 61.7% (127/206; P &lt; 0.001) of LEBQ2W were improved or cleared vs. 18.9% (20/106) of placebo. In ADhere at baseline, facial dermatitis was identified in 72.4% (105/145) of LEBQ2W patients and 59.1% (39/66) of placebo. At Week 16, 68.6% (72/105; P = 0.02) of LEBQ2W were improved or cleared vs. 46.2% (18/39) of placebo. At baseline, hand dermatitis was identified in 71.0% (103/145) of LEBQ2W patients and 66.7% (44/66) of placebo. At Week 16, 72.8% (75/103; P = 0.001) of LEBQ2W were improved or cleared vs. 43.2% (19/44) of placebo. Lebrikizumab treatment is efficacious in improving and clearing hand and face dermatitis in most patients at Week 16." @default.
• W4381336668 created "2023-06-21" @default.
• W4381336668 creator A5001401093 @default.
• W4381336668 creator A5017906399 @default.
• W4381336668 creator A5020923397 @default.
• W4381336668 creator A5025634637 @default.
• W4381336668 creator A5043652725 @default.
• W4381336668 creator A5068691017 @default.
• W4381336668 creator A5075941841 @default.
• W4381336668 creator A5079812104 @default.
• W4381336668 creator A5081529497 @default.
• W4381336668 creator A5087583072 @default.
• W4381336668 creator A5088950279 @default.
• W4381336668 date "2023-06-01" @default.
• W4381336668 modified "2023-10-02" @default.
• W4381336668 title "381 Improved and cleared facial and hand dermatitis with lebrikizumab in patients with moderate-to-severe atopic dermatitis" @default.
• W4381336668 doi "https://doi.org/10.1093/bjd/ljad162.009" @default.
• W4381336668 hasPublicationYear "2023" @default.
• W4381336668 type Work @default.
• W4381336668 citedByCount "0" @default.
• W4381336668 crossrefType "journal-article" @default.
• W4381336668 hasAuthorship W4381336668A5001401093 @default.
• W4381336668 hasAuthorship W4381336668A5017906399 @default.
• W4381336668 hasAuthorship W4381336668A5020923397 @default.
• W4381336668 hasAuthorship W4381336668A5025634637 @default.
• W4381336668 hasAuthorship W4381336668A5043652725 @default.
• W4381336668 hasAuthorship W4381336668A5068691017 @default.
• W4381336668 hasAuthorship W4381336668A5075941841 @default.
• W4381336668 hasAuthorship W4381336668A5079812104 @default.
• W4381336668 hasAuthorship W4381336668A5081529497 @default.
• W4381336668 hasAuthorship W4381336668A5087583072 @default.
• W4381336668 hasAuthorship W4381336668A5088950279 @default.
• W4381336668 hasConcept C126322002 @default.
• W4381336668 hasConcept C126894567 @default.
• W4381336668 hasConcept C138944611 @default.
• W4381336668 hasConcept C142724271 @default.
• W4381336668 hasConcept C16005928 @default.
• W4381336668 hasConcept C204787440 @default.
• W4381336668 hasConcept C27081682 @default.
• W4381336668 hasConcept C2778329239 @default.
• W4381336668 hasConcept C535046627 @default.
• W4381336668 hasConcept C71924100 @default.
• W4381336668 hasConceptScore W4381336668C126322002 @default.
• W4381336668 hasConceptScore W4381336668C126894567 @default.
• W4381336668 hasConceptScore W4381336668C138944611 @default.
• W4381336668 hasConceptScore W4381336668C142724271 @default.
• W4381336668 hasConceptScore W4381336668C16005928 @default.
• W4381336668 hasConceptScore W4381336668C204787440 @default.
• W4381336668 hasConceptScore W4381336668C27081682 @default.
• W4381336668 hasConceptScore W4381336668C2778329239 @default.
• W4381336668 hasConceptScore W4381336668C535046627 @default.
• W4381336668 hasConceptScore W4381336668C71924100 @default.
• W4381336668 hasIssue "Supplement_3" @default.
• W4381336668 hasLocation W43813366681 @default.
• W4381336668 hasOpenAccess W4381336668 @default.
• W4381336668 hasPrimaryLocation W43813366681 @default.
• W4381336668 hasRelatedWork W1989515154 @default.
• W4381336668 hasRelatedWork W2155174375 @default.
• W4381336668 hasRelatedWork W2437395753 @default.
• W4381336668 hasRelatedWork W2589009774 @default.
• W4381336668 hasRelatedWork W2603773804 @default.
• W4381336668 hasRelatedWork W3024829390 @default.
• W4381336668 hasRelatedWork W3030657224 @default.
• W4381336668 hasRelatedWork W4233016836 @default.
• W4381336668 hasRelatedWork W4381336668 @default.
• W4381336668 hasRelatedWork W2413468027 @default.
• W4381336668 hasVolume "188" @default.
• W4381336668 isParatext "false" @default.
• W4381336668 isRetracted "false" @default.
• W4381336668 workType "article" @default.